Wouter Zandee Profile
Wouter Zandee

@w_zandee

Followers
65
Following
120
Media
9
Statuses
121

Endocrinologist UMCG. Loves to run. Eat, sleep, work, train, repeat. Tweets are my own.

Joined May 2011
Don't wanna be here? Send us removal request.
@w_zandee
Wouter Zandee
10 months
RT @EJEndo: PRAP study—partial versus radical adrenalectomy in hereditary pheochromocytomas by Kai Xu et al. EJE Volume 191, Issue 3, Septe….
0
7
0
@w_zandee
Wouter Zandee
11 months
RT @EJEndo: #CoMICWednesday #EJECoMICs Ep 49: NEW @EJEndo paper: Partial versus Radical Adrenalectomy in Hereditary Pheochromocytomas .Watc….
0
6
0
@w_zandee
Wouter Zandee
3 years
RT @chana_weinstock: Our @FDAOncology approval summary for belzutifan, a first-in-class HIF inhibitor which is the first drug approved for….
0
31
0
@w_zandee
Wouter Zandee
3 years
Active Surveillance can especially be considered for microPTC. However tumors adjacent to the laryngeal nerve. ( and younger patients ( are not the best candidates.
liebertpub.com
Background: We showed previously that subclinical low-risk papillary thyroid microcarcinoma (PTMC) could be observed without immediate surgery. Patient age is an important prognostic factor of...
0
0
2
@w_zandee
Wouter Zandee
3 years
Debate on Active Surveillance for #thyroid carcinoma at #ENDO2022 with Mike Tuttle and Julie Sosa. "Active Surveillance is successful when it does not influence mortality and morbidity. Surgery after 2 years in not failure"
Tweet media one
1
3
4
@w_zandee
Wouter Zandee
4 years
RT @wijmenga_cisca: Hoe kan het toch dat een advies om de centra voor aangeboren hartafwijkingen in Leiden, Rotterdam en Groningen te conce….
0
271
0
@w_zandee
Wouter Zandee
4 years
An important development for our VHL patients!.
@NEJM
NEJM
4 years
Quick Take: Belzutifan for VHL-Disease–Associated Renal Cell Carcinoma
0
2
1
@w_zandee
Wouter Zandee
4 years
RT @EndoCancer: From the 2020 Impact Factor Collection: 'Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicen….
0
1
0
@w_zandee
Wouter Zandee
4 years
A great @net_connectinfo collaboration!.
@OncoThor
Thor Halfdanarson
4 years
Not sure what to do with those advanced well diff grade 3 NETs? Well, this excellent study will be of great interest to you. Excellent addition to the literature. Well done! @louis_demestier @JHernando3 @Ja_Capdevila @w_zandee and others
0
0
2
@w_zandee
Wouter Zandee
4 years
We report patients with stable disease and CS with symptoms despite SSA who were treated with PRRT. PRRT improved symptoms in this group with severe CS!.
@OncoThor
Thor Halfdanarson
4 years
PRRT for NETs - not just tumor control but also effective for control of carcinoid syndrome symptoms. Excellent work by @w_zandee et al. Clinically meaningful reduction in symptom burden. Definitely the kind of data we clinicians love to see.
0
1
8
@w_zandee
Wouter Zandee
4 years
RT @TheAAES: The incidence of pheochromocytoma has been increasing, as shown by this Dutch nationwide pathology registry. Although tumors a….
0
17
0
@w_zandee
Wouter Zandee
4 years
RT @DGlaucomflecken: Hanging out with the endocrinologist
0
1K
0
@w_zandee
Wouter Zandee
4 years
RT @OncoThor: Carcinoid crisis after a percutaneous liver biopsy, a nothingburger?? It sure looks so. 106 image-guided liver biopsies of NE….
0
5
0
@w_zandee
Wouter Zandee
4 years
Enjoying a proper Dutch winter: it’s been too long!
Tweet media one
Tweet media two
Tweet media three
0
0
0
@w_zandee
Wouter Zandee
5 years
Immunology for dummies.
@sargsyanz
Zaven Sargsyan
5 years
[Random loose mRNA lying around in a deltoid]. Nobody:. Ribosome: let me go ahead and transcribe this. Macrophage: Yo, check out this cool spike I found. T-cell: wtf is that? Get rid of it. Where’s Bob?. B-cell: yes?. T-cell: If it ever shows up here again. B-cell: yes mam.
0
0
1
@w_zandee
Wouter Zandee
5 years
Great team!.
@NeuroEndoTalk
NeuroEndoTalk
5 years
#Somatostatin analogs are regularly used as first line for GEP-#NETs. But what about #panNETs with Ki-67 Scores above 10%?.@cives_mauro, @Prof_M_C, @JHernando3, @T_AlonsoGordoa, @w_zandee and colleagues have explored this. The results may surprise some!.
1
1
3
@w_zandee
Wouter Zandee
5 years
Al met al: de weg omlaag is nog niet gevonden. Hoe je de getallen ook interpreteert.
0
0
1
@w_zandee
Wouter Zandee
5 years
SSTR-negative NET patients continue to have a worse prognosis compared to SSTR-positive NET patients despite receiving more aggressive treatment.
@HansHofland1
Hans Hofland
5 years
Now online @EndoCancer: excellent work from our Swiss fellow Julie Refardt 👏 on the worse prognosis of patients with somatostatin receptor-negative NETs #netcancer @ErasmusMC
0
0
3
@w_zandee
Wouter Zandee
5 years
Anti-SSTR2 antibody-drug conjugate for treatment of NETs was effective and well tolerated in mouse models
0
2
5